We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Viibryd (vilazodone hydrochloride)

  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Viibryd (vilazodone hydrochloride)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Viibryd (vilazodone hydrochloride) is a selective serotonin reuptake inhibitor and a 5HT1A receptor partial agonist. The mechanism of the antidepressant effect of vilazodone is not fully understood

    Viibryd is specifically indicated for the treatment of major depressive disorder.

    The recommended initial dose of Viibryd is 40 mg once daily. Treatment should be titrated, starting with an initial dose of 10 mg once daily for 7 days, followed by 20 mg once daily for an additional 7 days, and then an increase to 40 mg once daily.

    Clinical Results

    FDA Approval
    The FDA approval of Viibryd was based on two 8-week, multicenter, randomized, double-blind, placebo-controlled studies in adults meeting the criteria for major depressive disorder. The subjects were titrated over two weeks to a dose of 40 mg (n=436) or placebo (n = 433) once daily. Viibryd was superior to placebo in the improvement of depressive symptoms as measured by the mean change from baseline to Week 8 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score. In Study 1, the Least Squares Mean difference from placebo in change from baseline was -3.2 and in Study 2, the difference was -2.5.

    Side Effects

    Adverse events associated with the use of Viibryd may include, but are not limited to, the following:

    • diarrhea
    • nausea
    • vomiting
    • insomnia

    Mechanism of Action

    Viibryd (vilazodone hydrochloride) is a selective serotonin reuptake inhibitor and a 5HT1A receptor partial agonist. The mechanism of the antidepressant effect of vilazodone is not fully understood but is thought to be related to its enhancement of serotonergic activity in the CNS through selective inhibition of serotonin reuptake. Vilazodone is also a partial agonist at serotonergic 5-HT1A receptors; however, the net result of this action on serotonergic transmission and its role in vilazodone’s antidepressant effect are unknown.

    Literature References

    Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, Reed CR Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. The Journal of Clinical Psychiatry 2009 Mar;70(3):326-33. Epub 2009 Mar 10

    Additional Information

    For additional information regarding Viibryd or major depressive disorder, please visit the Viibryd web page.

    Approval Date: 2011-01-01
    Date Created: 2011-01-31 12:00:00
    Company Name: Clinical Data
    Back to Listings

    Upcoming Events

    • 09Dec

      The Age of eSource: Modernizing Clinical Trials

    • 16Dec

      Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

    Featured Products

    • Regenerative-medicine-steps-to-accelerate-development-pdf

      Regenerative Medicine: Steps to Accelerate Development — PDF

    • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

      Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

    Featured Stories

    • Patient-phsyician-consultation

      Giving Patients Back Their Voice in Clinical Trials

    • Ich_logo

      ICH Overhauls 22-Year-Old Clinical Studies Guideline

    • Survey_chart2019

      Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

    New!

    2019 Site Survey Reports

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing